Tocilizumab

Generic Name: Tocilizumab

Brand Names: Actemra, RoActemra, Tyenne, Tofidence

Drug Type: Biotech

Chemical Formula: -

CAS Number: 375823-41-9

Unique Ingredient Identifier: I031V2H011

Background: Tocilizumab is a recombinant humanized monoclonal antibody IL-6 receptor inhibitor used to treat inflammatory and autoimmune conditions. It was first described in the literature in 2003 when Chugai, a subsidiary of Roche began developing IL-6 inhibiting monoclonal antibodies. Tocilizumab was granted FDA approval on 8 January 2010 to treat a number of inflamm...

Indication: Tocilizumab is indicated to treat moderate to severe rheumatoid arthritis, giant cell arteritis, systemic sclerosis-associated interstitial lung disease, polyarticular juvenile idiopathic arthritis, systemic juvenile idiopathic arthritis, and cytokine release syndrome.
...

Associated Conditions: Coronavirus Disease 2019 (COVID‑19), Cytokine Release Syndrome caused by CAR-T Cell Therapy, Giant Cell Arteritis (GCA), Juvenile Chronic Polyarthritis, Moderate to Severe Rheumatoid Arthritis, Moderately to Severely Active Rheumatoid Arthritis, Polyarticular Juvenile Idiopathic Arthritis, Systemic Juvenile Idiopathic Arthritis (SJIA), Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD), Active systemic Juvenile idiopathic arthritis, Severe, active Rheumatoid arthritis

Associated Therapies: Monotherapy

Clinical Trials

A Study of Tocilizumab (RoActemra/Actemra) in Patients With Ankylosing Spondylitis Who Have Had an Inadequate Response to Previous Tumor Necrosis Factor (TNF) Antagonist Therapy

Phase 3

Terminated

Conditions: Spondylitis, Ankylosing

Interventions: Drug: Placebo
Drug: Tocilizumab

First Posted Date: 2010-09-27

Last Posted Date: 2013-01-17

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 113

Registration Number: NCT01209689

A Study of Tocilizumab (RoActemra/Actemra) Versus Adalimumab in Patients With Rheumatoid Arthritis

Phase 4

Completed

Conditions: Rheumatoid Arthritis

Interventions: Drug: Tocilizumab
Drug: Adalimumab
Drug: Placebo to adalimumab
Drug: Placebo to tocilizumab

First Posted Date: 2010-05-10

Last Posted Date: 2013-02-11

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 326

Registration Number: NCT01119859

Success of Tocilizumab in RA Patients With Remission Induction and Sustained Efficacy After Discontinuation

Phase 4

Completed

Conditions: Rheumatoid Arthritis

Interventions: Drug: Tocilizumab
Drug: Tocilizumab plus methotrexate

First Posted Date: 2010-05-10

Last Posted Date: 2015-01-26

Lead Sponsor: SURPRISE Study Group

Target Recruit Count: 233

Registration Number: NCT01120366

Locations: 🇯🇵
Utazu Hama Clinic, Ayautagun, Japan
🇯🇵
Hokkaido Medical Center for Rheumatic Diseases Hospital, Sapporo, Hokkaido, Japan
🇯🇵
Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Bunkyo-ku, Japan

and more 27 locations

Tocilizumab for Relapsing Polychondritis

Phase 2

Withdrawn

Conditions: Relapsing Polychondritis

First Posted Date: 2010-04-15

Last Posted Date: 2014-05-13

Lead Sponsor: McMaster Children's Hospital

Registration Number: NCT01104480

Locations: 🇨🇦
McMaster Children's Hospital, Hamilton, Ontario, Canada

Role of Interleukin-6 in Exercise

Not Applicable

Completed

Conditions: Diabetes Mellitus, Type 2
Obesity

Interventions: Behavioral: Sport
Drug: Tocilizumab
Drug: Sitagliptin

First Posted Date: 2010-02-23

Last Posted Date: 2016-11-01

Lead Sponsor: University of Zurich

Target Recruit Count: 56

Registration Number: NCT01073826

Locations: 🇨🇭
University Hospital Zurich, Zurich, Switzerland

A Study of Tocilizumab in Combination With an Oral Contraceptive in Patients With Rheumatoid Arthritis

Phase 3

Completed

Conditions: Rheumatoid Arthritis

Interventions: Drug: Tocilizumab
Drug: Ortho-Novum® 1/35

First Posted Date: 2010-01-08

Last Posted Date: 2013-04-01

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 46

Registration Number: NCT01044498

Single Patient Study to Treat Relapsing Polychondritis With Tocilizumab

Not Applicable

Completed

Conditions: Relapsing Polychondritis

Interventions: Drug: Tocilizumab

First Posted Date: 2009-12-31

Last Posted Date: 2021-03-03

Lead Sponsor: Children's Hospital of Eastern Ontario

Target Recruit Count: 1

Registration Number: NCT01041248

Locations: 🇨🇦
Children's Hospital of Eastern Ontario, Ottawa, Ontario, Canada

A Study of Tocilizumab as Monotherapy and in Combination With Methotrexate Versus Methotrexate in Patients With Early Moderate to Severe Rheumatoid Arthritis

Phase 3

Completed

Conditions: Rheumatoid Arthritis

Interventions: Drug: Tocilizumab
Drug: Placebo to tocilizumab
Drug: Placebo to methotrexate
Drug: Methotrexate

First Posted Date: 2009-11-04

Last Posted Date: 2017-07-26

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 1162

Registration Number: NCT01007435

Locations: 🇺🇸
Wenatchee Valley Hospital & Clinics, Wenatchee, Washington, United States
🇦🇺
Royal Prince Alfred Hospital; Rheumatology, Camperdown, New South Wales, Australia
🇺🇸
Ohio State University; Dept of Immunology, Columbus, Ohio, United States

and more 233 locations